Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
Where dulaglutide shines is in its cardiovascular data and its ease of use
This is a great option for patients who may be frightened by a needle going into their vein or muscle
LY3298176 was characterised in vitro, using signaling and functional assays in cell lines expressing recombinant or endogenous incretin receptors, and in vivo using body weight, food intake, insulin secretion and glycemic profiles in mice
Concentrate on activities with minimal impact to prevent excessive strain
For microdoses, it creates a problem